Treatment of severe pulmonary hemorrhage with activated recombinant factor VII (rFVIIa) in very low birth weight infants.
Clinically apparent pulmonary hemorrhage (PH) occurs in 5% to 7% of very low birth weight (VLBW) infants with respiratory distress syndrome (RDS). It is associated with a mortality rate as high as 50% and significant pulmonary and central nervous system morbidities. There is no consensus on treatment modality. We present two VLBW infants with severe PH that did not respond to conventional treatment but were successfully treated with activated recombinant factor VII (rFVIIa). No untoward side effects were noted.
Olomu
Nicholas
N
Department of Pediatrics and Human Development, Division of Neonatology, Michigan State University, East Lansing, MI 48909, USA.
Kulkarni
Roshni
R
Manco-Johnson
Marilyn
M
D015942:Factor VIIa / Q000627:therapeutic use*; D005260:Female; D006470:Hemorrhage / Q000188:drug therapy*; D006801:Humans; D007231:Infant, Newborn; D019102:Infant, Very Low Birth Weight; D008171:Lung Diseases / Q000188:drug therapy*; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use*; D012720:Severity of Illness Index
D011994:Recombinant Proteins; D015942:Factor VIIa